CYTR =MC $10 M -NDA/MAA filing in Q2 /many P3 and P2 program Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTR =MC $10 M -NDA/MAA filing in Q2 /many P3 and P2 program

CYTR 0.0920

0.0%

Oct 5 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext

From: BioHero	8/26/2020 1:37:28 PM
	of 7

GREAT BUYING OPP here ahead of the BLA acceptance expected next month Market Cap $21 M -Cash $14.6 M or Cash for 3 Years / Shares Out 33.6 M / 1 Orphan Drug with potential FDA approval in Q1 / 3 x Phase 3 Programs including 2 potential Blockbusters / has 2 BIG Orphan and Cancer Drug Pipeline / CYTRX has Drug deals worth $460 Million (see presentation below) = One of the MOST cheapest bio gem out there with MASSIV upside potential also a attractive takeover target at this low price . Price :0.58 New Presentation cytrx.com Orphan Drug Pipeline assets.wallstreet-online.de Cancer Pipeline assets.wallstreet-online.de

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext